MAB8293
Anti-Parvovirus B19 Antibody, aa 328-344 of VP2 capsid protein, clone R92F6
clone R92F6, Chemicon®, from mouse
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
ascites fluid
antibody product type
primary antibodies
clone
R92F6, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable
isotype
IgG1
shipped in
wet ice
Specificity
Recognizes Human parvovirus B19. Recognizes an epitope common to VP1 and VP2 structural proteins of B19. In B19 infected tissues, MAB8293 staining is localized predominantly in the nucleus though cytoplasmic staining may also be observed.
Immunogen
Epitope: a.a. 328-344 of VP2 capsid protein
Native parvovirus B19 purified from human plasma.
Application
Anti-Parvovirus B19 Antibody, aa 328-344 of VP2 capsid protein, clone R92F6 is an antibody against Parvovirus B19 for use in ELISA, IF, IH(P) & WB.
EIA: 1:200.
IFA: 1:200-1:400.
Immunohistochemistry on formalin-fixed paraffin-embedded tissue sections: 1:50-1:100. High temperature citrate buffer antigen retrieval is highly recommended.
Western Blot: 1:1,000.
Final working dilutions must be determined by end user.
IFA: 1:200-1:400.
Immunohistochemistry on formalin-fixed paraffin-embedded tissue sections: 1:50-1:100. High temperature citrate buffer antigen retrieval is highly recommended.
Western Blot: 1:1,000.
Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Physical form
Format: Purified
Liquid in 20mM Phosphate buffer, pH7.6, and 0.25M NaCl with 0.1% sodium azide as a preservative.
Protein A purified
Storage and Stability
Maintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Analysis Note
Control
Parvovirus positive patient sample
Parvovirus positive patient sample
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors.
T Lowin, U Raab, J Schroeder, R Franssila, S Modrow
Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health null
Wei-Ping Zhang et al.
Oncology letters, 8(2), 523-532 (2014-07-12)
In order to investigate the pathogenic mechanisms of parvovirus B19 in human colorectal cancer, plasmids containing the VP1 or VP2 viral capsid proteins or the NS1 non-structural proteins of parvovirus B19 were constructed and transfected into primary human colorectal epithelial
Parvovirus B19 infection in Hashimoto\'s thyroiditis, papillary thyroid carcinoma, and anaplastic thyroid carcinoma.
Adamson LA, Fowler LJ, Clare-Salzler MJ, Hobbs JA
Thyroid null
Ken Watanabe et al.
Stem cell research & therapy, 9(1), 80-80 (2018-03-29)
Latent microorganism infection is a safety concern for the clinical application of mesenchymal stem cells (MSCs). The aim of this study is to investigate the frequencies and sensitivities of the latent virus and mycoplasma infections in synovium, bone marrow, peripheral
HepG2 hepatocellular carcinoma cells are a non-permissive system for B19 virus infection.
Bonvicini, F; Filippone, C; Manaresi, E; Zerbini, M; Musiani, M; Gallinella, G
The Journal of General Virology null
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service